Late last year, Lilly was the first pharmaceutical stock to reach a $1 trillion valuation.

Eli Lilly's full-year guidance comes in stark contrast to the outlook of Novo Nordisk, which warned it sees sales and profit ...

The Indianapolis-based drugmaker reported revenue of $19.3 billion — up 43% from the same period a year ago, driven by growth ...

Mounjaro and Zepbound combined for $11.7 billion in the fourth quarter, which beat analyst consensus of $10.6 billion.

Eli Lilly beat profit estimates and issued strong guidance as demand for its weight-loss drugs surged, even as pricing ...

Despite some angst over pricing pressure for GLP-1 drugs, Lilly’s bullish projections surpassed consensus estimates, while ...

The rivalry in the GLP-1 market between pharmaceutical leaders Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) has ...

After Novo Nordisk projected yesterday that its revenue could decline by as much as 13% in 2026, its share price has ...

After a lackluster first half of 2025, healthcare stocks staged a comeback, posting the best performance among the 11 S&P 500 ...

Eli Lilly (LLY) stock rises after Q4 2025 earnings beat and strong 2026 outlook following a drop led by an underwhelming ...

Eli Lilly stock jumps 8% after Q4 earnings beat. Revenue hits $19.3B driven by Mounjaro and Zepbound sales growth.

Our community shared deeply mixed experiences of Ozempic and Mounjaro, with many warning of severe and sometimes debilitating ...